---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-040664"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:46:39.848821+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunocore Q3 2025 KIMMTRAK sales $103.7M, up 29% YoY; net loss $0.2M vs profit $8.7M

## Summary
- KIMMTRAK net revenue $103.7M (Q3); $295.5M YTD, up 31% YoY; US sales $67.3M, Europe $33.5M.
- Net loss $(0.2)M vs profit $8.7M in Q3 2024; diluted EPS $(0.00) vs $0.17.
- IDMC recommended 160 mcg dose for brenetafusp in Phase 3 PRISM-MEL-301; on track to complete enrollment in 1H 2026.
- Cash, equivalents & marketable securities $892.4M as of Sept 30, 2025; expects $65M rebate payments in Q4.
- Phase 3 TEBE-AM (tebentafusp) enrollment on track for 1H 2026 completion; multiple pipeline programs advancing.

## SEC filing metadata
- accession: 0001140361-25-040664
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036125040664/0001140361-25-040664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036125040664/ef20058378_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-040664
- JSON: https://secwatch.observer/filing/0001140361-25-040664.json
- Plain text: https://secwatch.observer/filing/0001140361-25-040664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.